# Baylor University

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/baylor-university/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 67.1 |
| Citations | 2,647,328 |
| City | Waco |
| Country | US |
| Description | Baylor University is a research organisation in Waco, US. OpenAlex records 41,459 works and 2,647,328 citations for it. 8,352 researchers list it as their most recent affiliation. |
| Homepage | https://www.baylor.edu |
| OpenAlex ID | https://openalex.org/I157394403 |
| Researchers | 8,352 |
| ROR ID | https://ror.org/005781934 |
| Type | education |
| Wikidata ID | https://www.wikidata.org/wiki/Q812573 |
| Works | 41,459 |

## University papers

Showing 12 of 67.

- [Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013](https://scholariq.org/papers/global-regional-and-national-incidence-prevalence-and-years-lived-with/)
- [Pembrolizumab for Early Triple-Negative Breast Cancer](https://scholariq.org/papers/pembrolizumab-for-early-triple-negative-breast-cancer/)
- [Global Distribution of Perfluorooctane Sulfonate in Wildlife](https://scholariq.org/papers/global-distribution-of-perfluorooctane-sulfonate-in-wildlife/)
- [Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer](https://scholariq.org/papers/phase-iii-trial-of-nanoparticle-albumin-bound-paclitaxel-compared-with/)
- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition](https://scholariq.org/papers/global-regional-and-national-disability-adjusted-life-years-dalys-for-306/)
- [Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-in-metastatic-triple-negative-breast-cancer/)
- [Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine](https://scholariq.org/papers/phase-1-2-trial-of-a-sars-cov-2-recombinant-spike-protein-nanoparticle-vaccine/)
- [Peer Reviewed: Perfluorochemical Surfactants in the Environment](https://scholariq.org/papers/peer-reviewed-perfluorochemical-surfactants-in-the-environment/)
- [RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer](https://scholariq.org/papers/ribbon-1-randomized-double-blind-placebo-controlled-phase-iii-trial-of/)
- [Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer](https://scholariq.org/papers/updated-results-from-monaleesa-2-a-phase-iii-trial-of-first-line-ribociclib-plus/)
- [Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer](https://scholariq.org/papers/sacituzumab-govitecan-hziy-in-refractory-metastatic-triple-negative-breast/)

## University researchers

- [Joyce O’Shaughnessy](https://scholariq.org/researchers/joyce-o-shaughnessy/)
- [Hyeong‐Moo Shin](https://scholariq.org/researchers/hyeong-moo-shin/)
- [Matthew Asare](https://scholariq.org/researchers/matthew-asare/)
- [David J. Tennent](https://scholariq.org/researchers/david-j-tennent/)
- [Kathleen McDeavitt](https://scholariq.org/researchers/kathleen-mcdeavitt/)

## University top topics

Showing 8 of 21.

- [Particle physics theoretical and experimental studies](https://scholariq.org/topics/particle-physics-theoretical-and-experimental-studies/)
- [High-Energy Particle Collisions Research](https://scholariq.org/topics/high-energy-particle-collisions-research/)
- [Quantum Chromodynamics and Particle Interactions](https://scholariq.org/topics/quantum-chromodynamics-and-particle-interactions/)
- [Religion, Spirituality, and Psychology](https://scholariq.org/topics/religion-spirituality-and-psychology/)
- [Religion and Society Interactions](https://scholariq.org/topics/religion-and-society-interactions/)
- [Religion, Society, and Development](https://scholariq.org/topics/religion-society-and-development/)
- [Cosmology and Gravitation Theories](https://scholariq.org/topics/cosmology-and-gravitation-theories/)
- [Geology and Paleoclimatology Research](https://scholariq.org/topics/geology-and-paleoclimatology-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.